 hit drug failure shares drug closed trade failure drug major clinical trial lung cancer drug significantly prolong survival patients disease setback group follows rejection pill major money spinners cholesterol drug facing mounting safety concerns blockbuster drugs meant power company forward failing got risks nick turner analyst brokers hoped pitch drug rival medicine proved better placebo extending lives trial involving 1,692 patients pharmaceuticals proved successful helping prolong life lung cancer patients appointed new executive director board john charge drug development company make substantial changes clinical processes determined improve development regulatory performance restore confidence company value shareholders chief executive tom